Trials / Conditions / Lymphoid Malignancies

Lymphoid Malignancies

19 registered clinical trials studyying Lymphoid Malignancies — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy NCT06047886	University of Alabama at Birmingham	Phase 1
Completed	Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies NCT05371054	National Cancer Institute (NCI)	Phase 1 / Phase 2
Recruiting	The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies NCT04329728	AVM Biotechnology Inc	Phase 1 / Phase 2
Unknown	Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT NCT02452697	Cristina Gasparetto	Phase 2
Terminated	Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibi NCT02739360	Gilead Sciences	Phase 4
Completed	Intra-Osseous Co-Transplant of UCB and hMSC NCT02181478	Case Comprehensive Cancer Center	EARLY_Phase 1
Terminated	ACY-1215 for Relapsed/Refractory Lymphoid Malignancies NCT02091063	Jennifer Amengual	Phase 1 / Phase 2
Terminated	Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies NCT01998035	Columbia University	Phase 1 / Phase 2
Completed	Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies NCT01947140	Jennifer Amengual	Phase 1 / Phase 2
Terminated	Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System NCT01596127	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies NCT01705847	Gilead Sciences	Phase 1
Completed	Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies NCT01435447	Shanghai Jiao Tong University School of Medicine	Phase 2
Terminated	Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lym NCT00992732	HemaQuest Pharmaceuticals Inc.	Phase 2
Terminated	A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies NCT01013818	Human Genome Sciences Inc.	Phase 1
Completed	Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies NCT00820508	Chroma Therapeutics	Phase 1
Completed	A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies NCT00406809	AbbVie (prior sponsor, Abbott)	Phase 1 / Phase 2
Completed	Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation NCT00383994	M.D. Anderson Cancer Center	Phase 1
Completed	RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies NCT00529438	Biogen	Phase 1
Completed	RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies NCT00508807	M.D. Anderson Cancer Center	Phase 1